Dr. Masha Livhits is an Endocrine Surgeon and Assistant Professor of Surgery at UCLA. An exceptional achiever since childhood, she attended college at the age of 12 through the highly competitive Early Entrance Program at California State University, Los Angeles. She then received her medical degree at Washington University School of Medicine in St. Louis and was awarded the prestigious Sarnoff Foundation genetics research grant.
Dr. Livhits completed her general surgery training and endocrine surgery fellowship at UCLA. She is certified by the American Board of Surgery and is a member of the American College of Surgeons. Dr. Livhits has published widely in the area of improving surgical outcomes and quality of care. She is dedicated to combining knowledge learned through research with her experience as a surgeon to deliver the best care to her patients. Her clinical and research interests include parathyroid disease, benign and malignant thyroid tumors, adrenal masses, and familial endocrine disorders. She helped to pioneer the new technique of single incision retroperitoneoscopic adrenalectomy in North America. She has an ongoing clinical trial to study molecular testing for thyroid nodules.
Pushing Through It
Amazing Cancer Facility
Experience with Dr. Livhitz
Left Adrenalcortical Carcinoma Surgery
First double adrenal gland removal at UCLA
My visit with UCLA Endocrine Surgery
My halloween adventure
Dr. Livhits and the team works as one!
One lump turned into ten!
Surgery For Hyperthyroidism “Sure Worth It”
Complete thyroidectomy and adjacent lymph nodes
Papillary Thyroid Carcinoma
Recovery from Parathyroid Surgery
My post thyroidectomy
Small Cut, Big Results
1) Biochemical and Skeletal Outcomes of Parathyroidectomy for Normocalcemic (Incipient) Primary Hyperparathyroidism. Sho S, Kuo EJ, Chen AC, Li N, Yeh MW, Livhits MJ. Ann Surg Oncol. 2018 Nov 7.
2) Risk Factors for Readmission After Parathyroidectomy for Renal Hyperparathyroidism. Lee JD, Kuo EJ, Du L, Yeh MW, Livhits MJ. World J Surg. 2018 Oct 19.
3) Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer. Hung ML, Wu JX, Li N, Livhits MJ, Yeh MW. JAMA Surg. 2018 Aug 15.
4) Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules. Livhits MJ, Kuo EJ, Leung AM, Rao J, Levin M, Douek ML, Beckett KR, Zanocco KA, Cheung DS, Gofnung YA, Smooke-Praw S, Yeh MW. J Clin Endocrinol Metab. 2018 Jun 1;103(6):2261-2268.
5) Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015. Park KW, Wu JX, Du L, Leung AM, Yeh MW, Livhits MJ. J Clin Endocrinol Metab. 2018 Mar 1;103(3):1095-1101.
6) Recent Pregnancy Is Not Associated with High-Risk Pathological Features of Well-Differentiated Thyroid Cancer. Chen AC, Livhits MJ, Du L, Wu JX, Kuo EJ, Yeh MW, Leung AM. Thyroid. 2018 Jan;28(1):68-71.
7) Individualizing Surgery in Papillary Thyroid Carcinoma Based on a Detailed Sonographic Assessment of Extrathyroidal Extension. Kuo EJ, Thi WJ, Zheng F, Zanocco KA, Livhits MJ, Yeh MW. Thyroid. 2017 Dec;27(12):1544- 1549.
8) Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma. Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ. JAMA Surg. 2018 Jan 1;153(1):52-59.
9) Factors Associated With Discordance Between Preoperative Parathyroid 4-Dimensional Computed Tomographic Scans and Intraoperative Findings During Parathyroidectomy. Sho S, Yuen AD, Yeh MW, Livhits MJ, Sepahdari AR. JAMA Surg. 2017 Dec 1;152(12):1141-1147.
10) Single-incision retroperitoneoscopic adrenalectomy: a North American experience. Sho S, Yeh MW, Li N, Livhits MJ. Surg Endosc. 2017 Jul;31(7):3014-3019.
Note: News website links may expire without notice.